Cancer Med:中国科学家新成果!特殊的外泌体分子或能改善抗癌药物向肿瘤的运输效率!

2022-04-27 生物谷 生物谷

来自中国南京大学医学院等机构的科学家们通过研究发现,外泌体或许能作为一种有效的载体来运输癌症疗法至肿瘤中,外泌体是一种能将分子从一个细胞转移到另一个细胞的特殊胞外囊泡分子。

外泌体是细胞间交流的重要介导子,因为其能在细胞间转运蛋白质和RNAs,由于其具有肿瘤靶向性能力、免疫兼容性、较低的毒性以及较长的半衰期,因此,间质干细胞衍生的外泌体或许有望帮助科学家们开发新型的抗肿瘤策略。

近日,一篇发表在国际杂志Cancer Medicine上题为“Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancer”的研究报告中,来自中国南京大学医学院等机构的科学家们通过研究发现,外泌体或许能作为一种有效的载体来运输癌症疗法至肿瘤中,外泌体是一种能将分子从一个细胞转移到另一个细胞的特殊胞外囊泡分子。

特殊的外泌体分子或能改善抗癌药物向肿瘤的运输效率。图片来源:Unsplash/CC0 Public Domain

这项研究中,研究人员利用被称之为脂质衍生的间质干细胞(ADSCs,adipose-derived mesenchymal stem cells)的特殊细胞所产生的外泌体来运输基于RNA(miR-138-5p)的抗癌疗法,从而有效治疗小鼠机体的膀胱癌。研究者表示,本文研究结果表明,ADSC衍生的外泌体或许能作为一种在体内运输小型分子药物的有效运输载体,而且外泌体所运输的miR-138-5p或许也能作为一种有效治疗膀胱癌的潜在治疗性制剂。

外泌体运输的miR-138-5p或许能在体外有效预防膀胱癌细胞的迁移、侵袭和增殖,此外,ADSC衍生的外泌体还能渗入肿瘤组织并成功运输miR-138-5p,从而成功在体内抑制异种移植肿瘤的生长。综上,本文研究结果表明,ADSC衍生的外泌体或许能作为一种有效的运输工具,以便在体内进行小分子药物的运输,而且外泌体所运输的miR-138-5p也能作为一种非常有潜力的治疗性制剂来促进膀胱癌患者的治疗。

原始出处:

Tianyao Liu, Tianhang Li, Yufeng Zheng, et al. Evaluating adipose-derived stem cell exosomes as miRNA drug delivery systems for the treatment of bladder cancerCancer Medicine (2022). DOI: 10.1002/cam4.4745

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
    2022-12-04 wgx306
  2. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
    2022-04-28 sunylz
  5. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1922232, encodeId=1eac1922232e4, content=<a href='/topic/show?id=33915836275' target=_blank style='color:#2F92EE;'>#新成果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=58362, encryptionId=33915836275, topicName=新成果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4193478, createdName=wgx306, createdTime=Sun Dec 04 22:02:50 CST 2022, time=2022-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024406, encodeId=5077202440677, content=<a href='/topic/show?id=79f4219392b' target=_blank style='color:#2F92EE;'>#中国科学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21939, encryptionId=79f4219392b, topicName=中国科学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=66ec123, createdName=guihongzh, createdTime=Sun Aug 28 03:02:50 CST 2022, time=2022-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308281, encodeId=c4e81308281c3, content=<a href='/topic/show?id=6e495554550' target=_blank style='color:#2F92EE;'>#抗癌药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55545, encryptionId=6e495554550, topicName=抗癌药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1314901, encodeId=ac391314901de, content=<a href='/topic/show?id=9d4b5554131' target=_blank style='color:#2F92EE;'>#抗癌药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55541, encryptionId=9d4b5554131, topicName=抗癌药)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517022, encodeId=d0d7151e022af, content=<a href='/topic/show?id=f1232194031' target=_blank style='color:#2F92EE;'>#中国科学家#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=21940, encryptionId=f1232194031, topicName=中国科学家)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cbca11021083, createdName=12498e5fm15(暂无昵称), createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1611560, encodeId=ad56161156071, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Thu Apr 28 12:02:50 CST 2022, time=2022-04-28, status=1, ipAttribution=)]

相关资讯

“冷肿瘤”变“热肿瘤”!武汉大学在肿瘤免疫治疗领域取得新进展

研究发现,通过抑制去泛素化酶USP8的功能可以重塑免疫微环境,使冷肿瘤转变成热肿瘤,从而显著提高免疫检查点PD-1/PD-L1抗体对肿瘤的治疗效果。

Nature Nanotechnology:厦门大学刘刚团队开发新型纳米囊泡疫苗平台,可介导超强抗肿瘤免疫活性

现有肿瘤疫苗如新抗原疫苗及各种载体疫苗均依赖于在机体内与宿主 APC 的随机接触,不适当的接触可能导致免疫应答的沉默;同时,CD8+ T细胞的活化过度依赖于抗原交叉递呈,该递呈方式机制复杂且效率不高。

​Small:国家纳米科学中心基于天然纳米材料构建个性化多功能肿瘤原位疫苗

肿瘤疫苗已经成为人类抗击癌症的热门领域。理想的肿瘤疫苗可以将抗原和佐剂共同传递给抗原递呈细胞(如树突状细胞),诱导特异性免疫反应杀伤肿瘤细胞。

Nature子刊:华南理工王均/熊梦华等开发治疗癌症的pH超敏纳米去垢剂

pTNT的设计实现了在0.1的pH变化下膜裂解活性材料功能的精准控制,为肿瘤乃至耐药肿瘤的治疗提供了新策略和新思路。

DCR:肿瘤位置对腹腔镜低位直肠癌手术后结果的影响

本项研究证实前部位置是低位直肠癌局部复发、总生存期和无病生存期的独立危险因素。